Phase 1/2 Trial of Anti‐pd‐ligand 1 (Durvalumab) +/‐ Lenalidomide in Patients With Cutaneous T Cell Lymphoma: Preliminary Results of Phase 1 and Correlative Studies

Querfeld, Christiane; Zain, Jasmine; Jovanović-Talisman, Tijana; Wakefield, Devin L.; Kil, Sung Hee; Estephan, Renee; Young, Paul R.; Sanchez, James F.; Martínez, X.; Stiller, Tracey; Palmer, Joycelynne; Rosen, Steven T.

doi:10.1002/hon.205_2631

Search citation statements

Order By: Relevance

Paper Sections

Select...

Immune Checkpoint Inhibitors1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ICIs are being investigated in combination with targeted therapies. A phase I/II study of nine patients with refractory and advanced CTCL using the PD-L1 inhibitor durvalumab with lenalidomide demonstrated clinical activity ( 21 ). Seven (78%) achieved a response with two having 90% or more improvement in mSWAT.…”

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%

Harnessing the immune system in the treatment of cutaneous T cell lymphomas

et al. 2023

View full text Add to dashboard Cite

Cutaneous T cell lymphomas are a rare subset of non-Hodgkin’s lymphomas with predilection for the skin with immunosuppressive effects that drive morbidity and mortality. We are now appreciating that suppression of the immune system is an important step in the progression of disease. It should come as no surprise that therapies historically and currently being used to treat these cancers have immune modulating functions that impact disease outcomes. By understanding the immune effects of our therapies, we may better develop new agents that target the immune system and improve combinatorial treatment strategies to limit morbidity and mortality of these cancers. The immune modulating effect of therapeutic drugs in use and under development for cutaneous T cell lymphomas will be reviewed.

show abstract

Section: Immune Checkpoint Inhibitorsmentioning

confidence: 99%